HIGHLIGHTS
- who: Ruxolitinib and colleagues from the Sultan Qaboos University Med J, August, Vol22, Iss3, pp., Epub. , have published the article: Evaluation of Ruxolitinib versus Best Available, in the Journal: (JOURNAL)
- what: OS=overall survival; PFS=progression-free survival; CI=confidence interval; BAT=best available therapy; Hb=haemoglobin; WBC=white blood cell; LDH=lactate dehydrogenase; IPSS=International Prognostic Scoring System; ECOG-PS=Eastern Cooperative Oncology Group Performance Status Furthermore, the findings of this study demonstrated that ruxolitinib could affect the survival outcomes, as indicated by the improved OS and PFS of the ruxolitinib group of MF . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.